Heng Xie PhD - Director
KERMODE BIOTECHNOLOGIES

Dr. Heng Xie serves as the Chief Medical Officer at Shenzhen Salubris Pharmaceuticals Co., Ltd. and is a senior adviser to the Mayo Clinic Cancer Center in Rochester, the China National Cancer Center, the China National Center of Biomedical Analysis, and the China Health Promotion Foundation. Before joining Salubris, Dr. Xie held the position of Senior Medical Officer/Program Director in the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI).

​

In his role at the NCI, Dr. Xie oversaw the research bases for two major clinical trials (Southwest Oncology Group and ECOG-ACRIN) and directed investigator-initiated/NCI-supported phase I-III clinical trials. He chaired the Cancer Prevention and Control Concept Protocol Review Committee, approving new concepts and protocols for cancer trials, and was a standing member of the Data Safety Monitoring Committee (DSMC) for both SWOG and ECOG-ACRIN.

​

Prior to his work in the DCP, Dr. Xie served as a Medical Officer for the Cancer Therapy and Evaluation Program (CTEP) at the NCI for nine years and as the Supervisory Medical Officer – Branch Chief for the Division of Clinical Innovation at the National Center for Advancing Translational Sciences (NCATS) for five years. At the NCI, he oversaw surgical oncology and clinical oncology programs supporting phase I-III cancer treatment trials, and at NCATS, he managed the Clinical Translational Science Awards (CTSA) program. Dr. Xie evaluated numerous clinical trial protocols, published 14 funding initiatives, and received multiple NCI/NIH Merit Awards.

​

Before his 18 years of public service at the NCI/NIH, Dr. Xie was a surgeon in China. He then moved to the United States, where he earned a Ph.D. in Molecular and Cellular Pathology from the University of Alabama at Birmingham and an M.P.H. from Johns Hopkins University. He is certified by the Educational Commission for Foreign Medical Graduates. Dr. Xie completed his postdoctoral training at the NCI, focusing on epidemiology, biostatistics, and clinical trials. His research and publications have specialized in cell signal transduction, EGFR-mediated mechanisms of tumor metastasis, and genetic molecular epidemiology.